Salarius Pharmaceuticals and Decoy Therapeutics
Type: Merger agreement
Buyer: Salarius Pharmaceuticals, Inc.
Seller: Decoy Therapeutics, Inc.
Focus: IMP3ACT platform
Deal value: $6 million
Financial impact: The Salarius–Decoy merger, driven by financial pressures and strategic goals, combines Salarius’s assets with Decoy’s peptide-conjugate platform to create a stronger, innovation-focused biotech company.
Salarius Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on cancer treatments, and Decoy Therapeutics, Inc., a preclinical biopharmaceutical company advancing next-gen peptide conjugate therapeutics, have announced a merger agreement. Decoy will merge with a Salarius subsidiary, forming a new company called Decoy Therapeutics. This merger aims to drive value through Decoy's IMP3ACT platform, which rapidly designs innovative therapeutics targeting viral threats and diseases like respiratory infections and gastrointestinal oncology.
The merger will involve Salarius and Decoy’s equity interests being exchanged for Salarius' common stock and newly designated Series A Preferred Stock. The deal is contingent on raising at least $6 million from a qualified financing. The merged company plans to incorporate Salarius' SP-3164 protein degrader into a peptide-based PROTAC drug candidate and continue developing seclidemstat for hematologic cancers in a Phase 1/2 trial at MD Anderson Cancer Center, while exploring strategic alternatives for seclidemstat. The merger is structured as a stock-for-stock transaction, where all of Decoy’s outstanding equity interests will be exchanged for a combination of Salarius’ common stock and newly designated Series A Preferred Stock. The common stock exchange will be based on an exchange ratio, with the total common stock issued not exceeding 19.9% of Salarius’ outstanding shares as of January 10, 2025, minus any shares issued in private placements between January 10, 2025, and the effective time of the merger. The Series A Preferred Stock will have economic rights equivalent to common stock, but with limited voting rights. The final number of common stock shares and the Series A Preferred Stock to be issued at closing will be determined based on an exchange ratio that assumes a base value of $28.0 million for Decoy and $4.6 million for Salarius, subject to adjustments based on the cash amounts of both companies at closing (excluding proceeds from the qualified financing).
The IMP3ACT platform
The IMP3ACT platform utilizes peptide chemistry to design α-helical peptides through computational and machine learning (ML) tools. These peptides are then converted into multimeric conjugates by chemically attaching multiple copies to lipids or other appropriate membrane anchor moieties. This process enhances their drug-like characteristics and dosing flexibility, while extending their pharmacokinetic profile. Decoy’s technology has developed peptide-conjugates that are effective in vitro against several human coronaviruses, including all major SARS-CoV-2 variants of concern to date, as well as RSV A, RSV B, and hPIV3. In vivo, the technology has shown effectiveness against the SARS-CoV-2 delta variant. By incorporating ML algorithms in the design and synthesis of peptides, Decoy’s platform accelerates the development of lead molecules for preclinical testing, while simultaneously optimizing peptide-conjugates for improved affinity, binding specificity, resistance to proteases, pharmacokinetic properties, and manufacturability at an early commercial scale.
Five years' market revenue of Salarius Pharmaceuticals
Salarius Pharmaceuticals has experienced a continued decline in revenue since 2021, primarily due to its status as a pre-commercial biotechnology company. As of December 31, 2024, the company had not generated any revenue from product sales and remained in the clinical development phase with no approved or commercialized products. This ongoing lack of commercialization, combined with recurring operating losses, resulted in an accumulated deficit of $81.9 million. The financial downturn was influenced by several key factors. In 2023, Salarius recorded a one-time non-cash goodwill impairment charge, which significantly impacted its financial results. Additionally, both research and development (R&D) expenses and general and administrative (G&A) expenses were notably lower in 2023 compared to 2022. This reduction was partially attributed to the decision to idle a clinical trial in late 2022, which led to decreased R&D spending. Overall, Salarius’s financial challenges reflect the broader risks faced by early-stage biopharmaceutical companies that are still in the development phase and have yet to bring products to market.
Five years market revenue of Salarius Pharmaceuticals (2020-2024)
Fig 17: Market revenue of Salarius Pharmaceuticals
Market Impact of This Partnership
The merger between Salarius Pharmaceuticals and Decoy Therapeutics was shaped by a blend of financial pressures and strategic opportunities. Salarius, operating with limited cash reserves and reporting a net loss of $5.6 million in 2024, was seeking to strengthen its position by integrating with a partner that could provide both technological advancement and financial stability. The company also faced potential compliance challenges related to its continued listing on the Nasdaq, adding urgency to its strategic realignment. Decoy Therapeutics, known for its proprietary peptide-conjugate platform, saw the merger as an opportunity to expand its therapeutic portfolio and leverage Salarius’s existing assets, infrastructure, and industry expertise. The transaction was structured to reflect the strategic value Decoy brought to the combined entity, with Decoy’s investors receiving a majority ownership stake post-merger. Ultimately, the merger aimed to create a more robust and competitive biotechnology company, combining Salarius’s developmental assets with Decoy’s innovative technology to enhance long-term growth potential and value creation.
“Facing financial strain, Salarius merged with Decoy, granting majority ownership to Decoy investors to drive long-term growth”